Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week

Kymera Therapeutics, Inc. (NASDAQ:KYMR) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.

Our free stock report includes 2 warning signs investors should be aware of before investing in Kymera Therapeutics. Read for free now.

Following the upgrade, the most recent consensus for Kymera Therapeutics from its 18 analysts is for revenues of US$70m in 2025 which, if met, would be a meaningful 18% increase on its sales over the past 12 months. Losses are forecast to hold steady at around US$3.67 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$60m and losses of US$3.69 per share in 2025. So there's definitely been a change in sentiment in this update, with the analysts upgrading this year's revenue estimates, while at the same time holding losses per share steady.

Check out our latest analysis for Kymera Therapeutics

There were no major changes to the US$56.89 consensus price target despite the higher revenue estimates, with the analysts seeming to believe that ongoing losses have a larger impact on the valuation than growing sales.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Kymera Therapeutics' past performance and to peers in the same industry. The analysts are definitely expecting Kymera Therapeutics' growth to accelerate, with the forecast 25% annualised growth to the end of 2025 ranking favourably alongside historical growth of 18% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 18% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Kymera Therapeutics to grow faster than the wider industry.

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Kymera Therapeutics is moving incrementally towards profitability. They also upgraded their revenue estimates for this year, and sales are expected to grow faster than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Kymera Therapeutics.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates - from multiple Kymera Therapeutics analysts - going out to 2027, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.